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Abstract: This paper describes the synthesis and in vitro antimalarial activity against a P. 
falciparum 3D7 strain of some new 1-aryl-3-substituted propanol derivatives. Twelve of 
the tested compounds showed an IC50 lower than 1 µM. These compounds were also tested 
for cytotoxicity in murine J774 macrophages. The most active compounds were evaluated 
for in vivo activity against P. berghei in a 4-day suppressive test. Compound 12 inhibited 
more than 50% of parasite growth at a dose of 50 mg/kg/day. In addition, an FBIT test was 
performed to measure the ability to inhibit ferriprotoporphyrin biocrystallization. This data 
indicates that 1-aryl-3-substituted propanol derivatives hold promise as a new therapeutic 
option for the treatment of malaria. 
Keywords: antimalarial agents; benzo[b]thiophene; 1-aryl-3-substituted propanol 
derivatives; P. Falciparum; ferriprotoporphyrin 
 
1. Introduction  
Malaria is a major health disease with hundreds of millions of people being infected. 
Approximately 50% of the world’s population, mostly those living in the world’s poorest countries, 
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are at risk of malaria [1]. Every year, more than 500 million people become severely ill with malaria. 
Most cases and deaths occur in tropical and subtropical countries. Early diagnosis and prompt 
treatment are the basic elements needed for the control of this condition.  
Chloroquine was the most effective and widely used drug in malaria therapy because of its rapid 
onset of action, good tolerability and low cost. However, the increasing resistance of the malaria 
parasite Plasmodium falciparum to currently available drugs, and especially to chloroquine, demands a 
continuous effort to develop new effective therapeutic options [2]. 
The arylamine alcohols (Figure 1) are antimalarial drugs structurally derived from quinine. 
Mefloquine is considered a standard therapeutic agent for chloroquine-resistant malaria; however, its 
use is limited by high costs and the appearance of neuropsychiatric side effects [3]. The administration 
of halofantrine is highly effective, but has been severely restricted due to its potential to induce fatal 
adverse cardiac effects [4]. Lumefantrine, which is an analogue of halofantrine with no cardiac effects, 
is available coformulated with arthemether in an oral preparation [5]. 
Strains of P. falciparum that are resistant to chloroquine and many other antimalarial drugs have 
since emerged and this has created a near desperate situation, where the need for new, inexpensive 
antimalarial agents has become vital. Identification of new molecular scaffolds structurally unrelated 
to existing antimalarial agents represents a valuable strategy to bypass resistance phenomena. 
Figure 1. Antimalarial drugs: Arylaminealcohol derivatives. 
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More recently aminopropanol derivatives have been described as antimalarial agents [6-8], so we 
focused our attention on a series of 1-aryl-3-[4-arylpiperazin-1-yl]-1-propane derivatives synthesized 
by our group and recently published as antidepressants [9-12] (Figure 2). Our efforts have been 
Molecules 2009, 14 
 
4122
focused on identifying new antimalarial drug candidates. As a result, we thought that the structural 
similarity of our compounds with the active arylamine alcohols in Figure 1 could also be interesting. 
Therefore, after several months of coordinated work between the synthesis and experimental 
chemotherapy, we report the synthesis and the antimalarial activity of 1-aryl-3-substituted propanol 
derivatives. We carried out both in vitro and in vivo assays in order to determine whether our 
compounds have potential for being considered as future antimalarial drugs. In addition, we performed 
an easy in vitro test in order to measure the ability of the compounds to inhibit the biomineralization 
process from ferriprotoporphyrin IX to hemozoin, as a possible mechanism of action. 
2. Results and Discussion  
The synthesis of some of the tested compounds has been published previously [9-12] (see reference 
publications in Tables 1-3. Methods for the synthesis of compounds 6-10, 16, 28-35, 38, 40, 41, 44 and 
45 are presented in Schemes 1-3, while derivatives 1-5, 11-15, 17-27, 36, 37, 39, 42 and 43 were 
previously reported [9-11]. 
The benzo[b]thiophene derivatives 6-10 were prepared using the 1-(3-benzo[b]thio phenyl)-3-
chloropropan-1-one precursor IV previously synthesized by a Friedel-Craft acylation of 
benzo[b]thiophene as described in [12]. Ketones were obtained by a SN2 nucleophilic attack of the 
corresponding arylamine III to IV (Scheme 1). 
The ketone intermediates VI were prepared by condensation of the corresponding commercially 
available acetophenones V with the different aryl amines III via Mannich reactions[12] (Scheme 2). 
Scheme 1. Synthesis of benzo[b]thiophenyl propanol derivatives 6-10, 16 and 28-35. 
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Scheme 2. Synthesis of 1-aryl-3-substituted propanol derivatives 38, 40, 41, 44 and 45. 
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The 4-chloro-, 2-methoxy- and 3-methoxyphenyl piperazines were commercially available. The rest 
of the aryl amines were synthesized using the corresponding BOC-arylamines and p-nitrophenyl, p-
nitro-o-trifluoromethylphenyl and 2-quinoxalinyl aryl fluorides by an SNAr reaction [13] and 
subsequent removal of the BOC-group with HCl and acetic acid (Scheme 3).  
Scheme 3. Synthesis of the non-commercially available arylamines. 
F-Ar / K2CO3/ CH3CN
reflux 48 h.
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Finally, all the hydroxyl derivatives 11-46 were obtained by reduction of the corresponding 
carbonyl group with NaBH4 in methanol. All of the compounds were chemically characterized by thin 
layer chromatography (TLC), melting point (m.p.), infrared (IR) and nuclear magnetic resonance (1H-
NMR) spectra, as well as by elemental microanalysis. 
Forty-six compounds were evaluated for in vitro antimalarial activity against P. falciparum, and 
twelve of them showed good activity, with IC50 values lower than 1 µM. We paid special attention to 
compounds 12, 15, 22, 23 and 31 since they were the most active, only two to fourfold less active than 
chloroquine. On the other hand, twenty-nine compounds showed moderate or low activity with IC50 
values between 1 and 14.63 µM. All other compounds were considered to be inactive because they 
either showed no activity or their activity was quite insignificant (see Tables 1 and 2). Chloroquine, 
the positive control, showed an IC50 of 0.08 µM, which coincides with the value reported by other 
authors. 
Table 1. In vitro antimalarial activity of Benzo[b]thiophenyl derivatives versus 
Chloroquine Sensitive ·3D7 Strain of Plasmodium falciparum. 
S
R
AMINE Ar
Z
 
Compd. R Z Amine Ar P. falciparum 3D7 
IC50 M 
1a F C=O N
N
 1-naphthyl IN 
2 c F C=O N
N
 2-methoxyphenyl IN 
3 b H C=O N
N
 2-methoxyphenyl IN 
4a F C=O N
N
 8-quinolyl IN 
5a H C=O N
N
 8-quinaldinyl IN 
6 H C=O N
N
 4-nitro-2-trifluromethyl phenyl IN 
7 H C=O 
N NH  4-nitro-2-trifluromethyl phenyl IN 
8 H C=O NNH  4-nitrophenyl IN 
9 H C=O N N  4-nitrophenyl IN 
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Table 1. Cont. 
10 H C=O N
N
 2-quinoxaline IN 
11a H OH N
N
 1-naphthyl 6.13 
12a F OH N
N
 1-naphthyl 0.16 
13b H OH N
N
 2-methoxyphenyl 1.07 
14b H OH N
N
 2-hydroxyphenyl 13.73 
15c F OH N
N
 2-methoxyphenyl 0.33 
16 F OH N
N
 3-methoxyphenyl 1.67 
17a  H OH N
N
 4-indolyl 6.99 
18a F OH N
N
 4-indolyl 3.81 
19b H OH N
N
 4-chlorophenyl 5.65 
20a H OH N
N
 8-quinolyl 2.15 
21a F OH N
N
 8-quinolyl 0.79 
22a H OH N
N
 8-quinaldinyl 0,66 
23a F OH N
N
 8-quinaldinyl 0.38 
24a H OH N
N
 5-quinolyl 1.30 
25a H OH N
N
 2-quinolyl 2.22 
26a H OH N
N
 2,3-dihydro-1,4-benzodioxin-5-yl 3.56 
27a F OH N
N
 2,3-dihydro-1,4-benzodioxin-5-yl 0.90 
28 H OH N
N
 4-nitro-2-trifluromethyl phenyl 0.68 
29 H OH 
N NH  4-nitro-2-trifluromethyl phenyl 2.99 
30 H OH NH N  4-nitro-2-trifluromethyl phenyl 0.97 
31 H OH NNH  4-nitro-2-trifluromethyl phenyl 0.19 
32 F OH N
N
 4-nitrophenyl IN 
33 H OH NNH  4-nitrophenyl 1.00 
34 H OH N N  4-nitrophenyl 3.43 
35 H OH N
N
 2-quinoxalinyl 0.62 
Chloroq.     0.08 
a Drugs from [11]; b Drugs from [9]; c Drugs from [10]. IC50 is the 50% inhibitory concentration of the in 
vitro parasite growth. Each value is the mean of two experiments in triplicate. All the compounds with IC50 
value higher than 20 µM was considered inactive (IN). 
 
From the point of view of the SAR and in order to assess the importance of the OH group present in 
the arylamine moiety, the in vitro antimalarial activity of some ketone intermediates (compounds 1-10) 
against P. falciparum was evaluated. It is important to point out that none of them were active. This 
fact suggests that the OH group present in the arylamine moiety is essential for the activity. In 
addition, an increase in the activity was observed in the benzothiophene derivatives, when substituted 
in position 5 with an electron withdrawing group (R=F; compounds 12, 15, 18, 21, 23, 27) in 
comparison with the corresponding unsubstituted derivatives (R=H; compounds 11, 13, 17, 20, 22, 
26). Regarding the different amines employed, the activity data suggest that the most interesting 
compounds are those containing the 4-aminopiperidine moiety (see compounds 28-31 and 32-34). 
Finally, it is evident that the presence of a benzocondensed group in Ar' (benzothiophenyl or naftyl) 
contributes to a notable improvement in the activity compared to other aromatic substituents. 
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Before testing the in vivo antimalarial activity, we evaluated the cytoxicity of every active 
compound on a murine macrophages J774 cell line. Although the majority of them were toxic at 100 
µg/mL, only compound 31 showed toxicity at 10 µg/mL. From our point of view, if a compound 
shows a toxicity percentage higher than 30% at this concentration, it will be toxic in vivo. However, 
we decided to include it in an in vivo test with mice (Table 3). Only compound 12 inhibited more than 
50% of parasite growth and the appearance of the mice was good at the end of the experiment. The 
mice in groups treated with compounds 23 and 15 looked unhealthy and showed clear evidence of 
weight loss. Unfortunately, the cytotoxicity of compound 31 was confirmed in the in vivo test. 
Ferriporotoporphyrin IX (FPIX) biocrystallization is a Plasmodium-specific process in which the 
toxic FPIX derived from the digestion of ingested haemoglobin is converted into an insoluble nontoxic 
crystalline species called haemozoin. This is the mechanism through which chloroquine exerts its 
antimalarial effect. Due to the structural similarity of our compounds with other antimalarial arylamine 
alcohol derivatives, we felt that it could be important to examine this. The results showed that no 
compound was active in the FBIT test. This fact supports the hypothesis that 1-aryl-3-substituted 
propanol derivatives, such as quinine, have a weaker binding coefficient to FP [14]. This was 
demonstrated by Deharo [15], who reported an IC50 = 324µM for quinine in the FBIT test. This fact is 
of great importance because the parasite has developed resistance to the majority of the antimalarials 
of the 4-aminoquinoline group, all of which inhibit the formation of haemozoin. 
Table 2. In vitro antimalarial activity of 1-aryl-3-substituted propanol derivatives versus 
Chloroquine Sensitive ·3D7 Strain of Plasmodium falciparum. 
Ar ' AMINE Ar
H OH
 
Compd. Ar’ Amine Ar 
P. falciparum 3D7
IC50 M 
36b 3-thiophenyl N
N
4-chlorophenyl IN 
37b phenyl N
N
4-chlorophenyl 13.04 
38 biphenyl N
N
4-chlorophenyl IN 
39b phenyl N
N
2-methoxyphenyl IN 
40 biphenyl N
N
2-methoxyphenyl 14.63 
41 3-indolyl N
N
2-methoxyphenyl IN 
42b 2-naphthyl N
N
2-methoxyphenyl 0.83 
43a 2,4- N
N
2-methoxyphenyl 16.91 
44 6-methylnapht-2- N
N
2-methoxyphenyl 9.64 
45 2-naphthyl NH N  4-nitro-2-trifluromethyl phenyl 9.10 
46a 2,4- N
N
2-hydroxyphenyl 18.16 
Chloroq.    0.08 
a Drugs from [11]; b Drugs from [9]. IC50 is the 50% inhibitory concentration of the in vitro parasite growth. 
Each value is the mean of two experiments in triplicate. All the compounds with IC50 value higher than 20 
µM was considered inactive (IN). 
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Table 3. In vivo antimalarial activity of selected 1-aryl-3-arylamino propanol derivatives 
against Plasmodium berghei ANKA strain. 
AMINE Ar
H OH
Ar '  
Compd. Ar’ Amine Ar 
GIP of  
P. bergei 
at 50 mg/kg/day 
12 5-F-Benzo[b]thiophenyl N
N
1-naphthyl 65,79 
23 5-F-Benzo[b]thiophenyl N
N
8-quinaldinyl 37,69 
15 5-F-Benzo[b]thiophenyl N
N
2-methoxyphenyl 24,73 
31 Benzo[b]thiophenyl NNH 4-NO2-2-CF3-phenyl Toxic 
Chloroq.    
100% at 10 
mg/kg 
GIP = Growth inhibition percentage of the rodent malaria parasite after a four-day treatment. 10 mg/kg/day 
of chloroquine, positive control, inhibited 100% the growth parasite. a Toxic = death of more than half of the 
animals in the tested group. 
3. Experimental  
3.1. Biological evaluation 
3.1.1. In vitro antimalarial activity screening against Plasmodium falciparum  
The SYBR©GreenI-based micromethod [16] was followed for testing the antimalarial activity of the 
compounds. Erythrocytic stages of P. falciparum 3D7 strain, chloroquine sensitive, were maintained in 
RPMI 1640 culture medium supplemented with 0.5% Albumax II at 37 ºC in an atmosphere with 5% 
CO2. An erythrocyte suspension, with initial 1% parasitemia and 4% hematocrit, was prepared using 
the aforementioned culture and then distributed into a 96-well plate, 50 µL per well. Next, stock 
solutions of each compound were prepared in DMSO and diluted in RPMI medium in order to obtain 
concentrations from 10 to 0.01 µg/mL. The final DMSO concentration was never higher than 0.1%.  
50 µL of each prepared concentration were added per well. DMSO and chloroquine were included as a 
negative and positive control, respectively. All compounds and controls were placed in triplicate. The 
plate was incubated under the same conditions. After 48 h, the plate was removed from the incubator 
and frozen for at least 1 h at -70 °C and then thawed. Finally, 100 µL of SYBR©GreenI in lysis buffer 
(0.2 µL/mL) was added per well and shaken for 5 minutes or until no precipitated erythrocytes were 
observed. The plate was left to stand in the dark for 1 h at room temperature. Fluorescence intensity 
(FI) for each well was measured. The background of the nonparasitized erythrocytes was subtracted 
from each well tested. Percentage inhibition of the parasite growth for each concentration was 
calculated by using the following formula:  
% inhibition = 100 × [(F.I.control – F.I.comp)/(F.I.control)] 
IC50 values were estimated by plotting drug concentration versus percentage inhibition. 
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3.1.2. Nonspecific cytotoxicity tests [17] 
Murine J774 macrophages were maintained in RPMI 1640 medium supplemented with 10% FBS at 
37 °C in a 5% CO2 atmosphere. First, in a flat bottom 96-well microplate, 100 µL of macrophage 
suspension in RPMI medium, containing 5 × 104 cells, were distributed per well. The cells were 
allowed to attach for 24 h at 37 °C. Next, the medium was replaced by different concentrations of the 
compounds in 200 µL of medium, or DMSO at the same concentration as growth control, and the cells 
were exposed to the compounds solutions for another 24 h. Each concentration was assayed three 
times. Afterwards, the medium was eliminated and 100 µL/well of 3-(4,5-dimethythiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) solution, 0.4 mg/mL in PBS, was added and the plates were 
returned to incubator for 1 h. The suspension was removed and the toxic effect of the compounds was 
assessed by the reduction of MTT to formazan crystals (as a cell viability indicator); said crystals were 
solubilized by adding 100 µL of DMSO. Finally, the optical density (OD) was measured at 595 nm 
and the toxicity percentage was calculated as follows: 
% toxicity = [(O.D.control - O.D.comp)/(O.D.control)] × 100 
3.1.3. In vivo antimalarial activity 
The in vivo antimalarial activity of the compounds was measured by the classical 4-day suppressive 
test [18]. Briefly, on day 0, groups of five NMRI male mice, weighing 20 ± 2 g each , were inoculated 
with 2 × 107 red blood cells RBCs infected by erythrocytic stages of rodent malaria parasite P. berghei 
ANKA strain. Two hours later, each group of mice was treated intraperitoneally with a dose of  
50 mg/kg of the selected compound, previously prepared in DMSO. Treatment was continued from 
day 1 to day 3, always at similar times. On day 4, Giemsa-stained thin blood smears from the tail of 
the mice were prepared and microscopically examined with 1,000× magnification. The mean of the 
parasitemia of each group was calculated in a total of 1,000 RBCs, and the growth inhibition 
percentage of parasite was estimated in relation to the control group, which received only the solvent 
of the products. 
% inhibition = [(Par control – Par comp)/(Par control)] × 100 
3.1.4. Ferriprotoporphyrin IX biomineralization inhibition test (FBIT) 
The procedure for testing FP biomineralization was carried out according to the method described 
by Deharo [15]. A mixture containing 50 µL of a 10 mg/mL drug solution or 50 µL of solvent (for 
control), 50 µL of 0.5 mg/mL of haemin chloride (Sigma H 5533) freshly dissolved in 
dimethylsulphoxide (DMSO) and 100 µL of 0.5 M sodium acetate buffer pH 4.4 was incubated in a 
non-sterile flat bottom 96-well plate at 37 °C for 18-24 hrs. After incubation, the plate was centrifuged 
at 1,600 g for 5 min and the supernatant was discarded. The remaining pellet was resuspended with 
200 µL of DMSO in order to remove unreacted FP. The plate was then centrifuged once again and the 
supernatant discarded. The pellet (precipitate of ß-haematin), was dissolved in 150 µL of 0.1 M NaOH  
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and the absorbance quantified at 405 nm with a microplate reader. The data was expressed as the 
percentage of inhibition of FP biomineralization, calculated using the following equation:  
% inhibition = 100 × [(O.D.control - O.D.drug)/(O.D.control)] 
3.2. Chemistry 
The 1H-NMR spectra were recorded on a Bruker 400 Ultrashield (400 MHz) (Bruker, Rheinstetten, 
Germany), using TMS as internal standard and chloroform (CDCl3) or dimethyl sulfoxide- d6 (DMSO-
d6) as solvents; the chemical shifts are reported in ppm (δ), and coupling constant (J) values are given 
in Hertz (Hz). Signal multiplicities are represented by: s (singlet), bs (broad singlet), d (doublet), t 
(triplet), q (quadruplet), dd (double doublet) and m (multiplet). The IR spectra were registered on a 
Thermo Nicolet FT-IR Nexus Euro (Thermo, Madison, WI, USA) using KBr pellets; the frequencies 
are expressed in cm-1. Elemental microanalyses were obtained on an Elemental Analyzer (LECO 
CHN-900, Leco, Tres Cantos Spain) from vacuum-dried samples. The analytical results for C, H, and 
N were within ± 0.4 of the theoretical values. Alugram SIL G/UV254 (Layer: 0.2 mm) (Macherey-
Nagel GmbH & Co. KG. Germany) was used for thin layer chromatography and silica gel 60  
(0.040–0.063 mm) for column flash chromatography (Merck). Chemicals were purchased from E. 
Merck (Darmstadt, Germany), Scharlau (F.E.R.O.S.A., Barcelona, Spain), Panreac Química S.A. 
(Montcada i Reixac, Barcelona, Spain), Sigma-Aldrich Química, S.A., (Alcobendas, Madrid, Spain, ), 
Acros Organics (Janssen Pharmaceuticalaan, Geel, Belgium) and Lancaster (Bischheim-Strasbourg, 
France). 
3.2.1. General method for the synthesis of protected aryl amines II 
A mixture of the aryl fluoride (1 eq), the protected amine I (1.2 eq), K2CO3 (1.2 eq) and CH3CN  
(50 mL) was heated at reflux for 48 hours. The solvent was removed under reduced pressure, the 
residue was dissolved in CH2Cl2 (50 mL) and washed with water (3 × 30 mL). The organic phase was 
dried with anhydrous Na2SO4 and filtered. After evaporating to dryness under reduced pressure, the 
residue was precipitated and washed by adding diethyl ether or petroleum ether, affording the desired 
protected aryl amine II. 
3.2.2. General method for the preparation of deprotected amines III 
The protected amine II was dissolved in 40 mL of a solution of HCl/AcOH (1:1) with stirring for  
2 hours at room temperature. The solvent was removed under reduced pressure and the compound was 
dissolved in water. The aqueous solution was basified with NaOH 2M to basic pH and stirred for  
1 hour. Then the product was extracted with CH2Cl2. The organic phase was dried with anhydrous 
Na2SO4 and filtered. After evaporating to dryness under reduced pressure the residue was precipitated 
and washed by adding diethyl ether or petroleum ether, affording the desired deprotected amine III. 
3.2.3. General method for the synthesis of ketones 6-10 
A mixture of 1-(benzo[b]thiophen-3-yl)-3-chloropropan-1-one IV (1 eq), the arylamine III (1.2 eq) 
and K2CO3 (1.2 eq) was stirred in THF (50 mL) for 72 hours at room temperature. The solvent was 
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removed under reduced pressure and the residue was dissolved in CH2Cl2 (40 mL) and washed with 
water (3 × 30 mL). After evaporating to dryness under reduced pressure the residue was purified by 
column chromatography (SP: silica gel), eluting with CH2Cl2/methanol 99:1 (v/v). In some cases the 
compound has been purified by preparative chromatography (SP: silica gel), eluting with 
CH2Cl2/methanol 95:5 (v/v). In the cases in which the hydrochloride salt was prepared, the process 
consisted in adding an ethereal hydrogen chloride solution to a dichloromethane solution of the 
compound. 
3.2.4. General method for the synthesis of ketones VI 
A mixture of the appropriated substituted acetophenone V (1 eq), arylamine III or a commercially 
available one (1 eq) in absolute EtOH (40 mL) and concentrated HCl (pH = 2-3) was heated at reflux. 
Paraformaldehyde (3 eq) was added in four equal portions over a period of 40 min. The reaction 
mixture was refluxed for another 24 h, cooled and poured onto crushed ice. The separated solid was 
filtered, dried and recrystallized from 1-propanol. 
3.2.5. General method for preparation of hydroxyl derivatives 16, 28-35, 38, 40, 41, 44 and 45 
Sodium borohydride (3 eq) was added little by little to a precooled suspension (0 ºC, 5 min) of the 
corresponding ketone (1 eq) in methanol (40 mL) over a period of 30-60 minutes. The solvent was 
removed under reduced pressure and the residue dissolved in dichloromethane (40 mL) was washed 
with water (3 x 30 mL). The organic phase was dried with anhydrous Na2SO4 and filtered. After 
evaporating the solvent to dryness under reduced pressure, the compound was purified by column 
chromatography (SP: silica gel), eluting with CH2Cl2/methanol 99:1 (v/v) or by preparative 
chromatography (SP: silica gel), eluting with CH2Cl2/methanol 95:5 (v/v). 
 
1-(Benzo[b]thiophen-3-yl)-3-[4-(4-nitro-2-trifluoromethylphenyl)piperazin-1-yl]propan-1-ona (6). 
Yield 3%; Mp 140-141 ºC; 1H-NMR (CDCl3): δ 2.76-2.77 (m, 4H, H2 + H6 piperazine); 3.02 (c, 2H, 
CO-CH2-CH2); 3.19-3.21 (t, 4H, H3 + H5 piperazine); 3.27-3.30 (c, 1H, CO-CH2-CH2); 7.29 (dd, 1H, 
H6’ phenyl, J6’,5’ = 9.4 Hz, J6’,3’ = 2.5 Hz ); 7.46 (t, 1H, H6 benzothiophenyl, J6,5 = 8.0 Hz); 7.52 (t, 1H, 
H5 benzothiophenyl, J5,4 = 8.1 Hz); 7.90 (d, 1H, H4 benzothiophenyl, J4,5 = 8.0 Hz); 8.33-8.36 (m, 2H, 
H5’ phenyl + H7 benzothiophenyl); 8.53 (s, 1H, H2 benzothiophenyl); 8.78 (d, 1H, H3’ phenyl) ppm; 
Anal. Calcd. for (C22H20N3F3O3S) C, 57.02; H, 4.32; N, 9.07. Found: C, 56.80; H, 4.53; N, 9.06. 
 
1-(Benzo[b]thiophen-3-yl)-3-[3-(4-nitro-2-trifluoromethylphenylamino)-(R)-pyrrolidin-1-yl] propan-
1-one (7). Yield 5%; Mp 98-100 ºC; 1H-NMR (CDCl3): δ 1.76-1.83 (m, 1H, H4ec pyrrolidine); 2.40-
2.48 (m, 1H, H4ax pyrrolidine); 2.60 (dd, 1H, H5ax pyrrolidine); 2.80 (dd, 1H, H2ec pyrrolidine); 2.93 
(dd, 1H, H2ax pyrrolidine); 3.00-3.10 (m, 3H, H5ec pyrrolidine + CO-CH2-CH2); 3.27 (t, 2H, CO-CH2, 
JCH2-CH2 = 6.8 Hz); 4.16 (s.a, 1H, H3 pyrrolidine); 5.37 (d, 1H, NH); 6.68 (d, 1H, H6’ phenyl, J6’,5’ = 9.3 
Hz); 7.45 (dd, 1H, H5 benzothiophenyl, J5,6 = 7.1 Hz, J5,4 = 8.0 Hz, J57 = 1.1 Hz); 7.51 (dd, 1H, H6 
benzothiophenyl, J6,5 = 7.2 Hz, J6,7 = 8.2 Hz, J6,4 = 1.1 Hz); 7.88 (dd, 1H, H4 benzothiophenyl, J4,5 = 
8.0 Hz, J46 = 1.0 Hz); 8.22 (dd, 1H, H5’ phenyl, J5’,6’ = 9.3 Hz, J5’,3’ = 2.3 Hz); 8.36 (s, 1H, H2 
benzothiophenyl); 8.39 (d, 1H, H3’ phenyl, J3’,5’ = 2.5 Hz); 8.77 (dd, 1H, H7 benzothiophenyl, J7,6 = 
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8.2 Hz, J7,5 = 1.0 Hz) ppm; Anal. Calcd. for (C22H20N3F3O3S) C, 57.02; H, 4.32; N, 9.07. Found: C, 
56.72; H, 4.32; N, 9.22. 
1-(Benzo[b]thiophen-3-yl)-3-[1-(4-nitrophenyl)piperidin-4-ylamino]propan-1-one (8). Yield 57%; Mp 
144-145 ºC; 1H-NMR (DMSO-d6): δ 1.22-1.31 (m, 2H, H3ax + H5ax piperidine); 1.79 (bs, 1H, NH); 
1.78 (dd, 2H, H3ec + H5ec piperidine); 2.71-2.78 (m, 1H, H4 piperidine); 2.95 (t, 2H, CO-CH2, JCH2-CH2 
= 6.6 Hz); 3.05-3.11 (m, 2H, H2ax + H6ax piperidine); 3.18 (t, 2H, CH2-NH, JCH2-CH2 = 6.6 Hz); 3.92 (d, 
2H, H2ec + H6ec piperidine); 7.00 (d, 2H, H2’ + H6’ phenyl, J2’,3’ = J6’,5’ = 9.6 Hz); 7.43-7.52 (m, 2H, H5 
+ H6 benzothiophenyl); 8.02 (d, 2H, H3’ + H5’ phenyl, J3’,2’ = J5’,6’ = 9.5 Hz); 8.08 (d, 1H, H4 
benzothiophenyl); 8.61 (d, 1H, H7 benzothiophenyl); 8.97 (s, 1H, H2) ppm; Anal. Calcd. for 
(C22H23N3O3S) C, 64.53; H, 5.66; N, 10.26. Found: C, 64.88; H, 5.67; N, 10.28.  
 
Hydrochloride of 1-(benzo[b]thiophen-3-yl)-3-[4-(4-nitrophenyl)-1,4-diazepan-1-yl]propan-1-one (9). 
Yield 57%; Mp 121-123 ºC; 1H-NMR (DMSO-d6): δ 2.22-2.28 (m, 1H, H6 diazepane); 2.43-246 (m, 
1H, H6 diazepane); 3.20-3.25 (m, 2H, H7 diazepane); 3.35 (m, 2H, CO-CH2-CH2); 3.53-3.56 (m, 2H, 
H2 diazepane); 3.63-3.67 (m, 2H, H5 diazepane); 3.70-3.72 (m, 2H, CO-CH2); 3.87-3.95 (m, 1H, H3 
diazepane); 4.03-4.09 (m, 1H, H3 diazepane); 6.92(d, 2H, H2’ + H6’ phenyl, J2’,3’ = J6’,5’ = 9.4 Hz); 
7.46-7.55 (m, 2H, H6 + H5 benzothiophenyl); 8.08-8.12 (m, 3H, H4 benzothiophenyl+ H3’+ H5’ 
phenyl); 8.60 (d, 1H, H7 benzothiophenyl, J7,6 = 8.1 Hz); 9.06 (s,1H, H2 benzothiophenyl); 10.95 (s.a., 
1H, HCl) ppm; Anal. Calcd. for (C22H23N3O3S·HCl) C, 59.25; H, 5.42; N, 9.42. Found: C, 58.86; H, 
5.69; N, 9.08. 
 
1-(Benzo[b]thiophen-3-yl)-3-[4-(quinoxalin-2-yl)piperazin-1-yl]propan-1-one (10). Yield 13%; Mp 
145-146 ºC; 1H-NMR (CDCl3): δ 2.74 (t, 4H, H2 + H6 piperazine); 3.00 (t, 2H, CO-CH2-CH2); 3.08 (t, 
2H, CO-CH2); 3.85 (t, 4H, H3 + H5 piperazine); 7.40-7.47 (m, 2H, H5 benzothiophenyl + H7’ 
quinoxalinyl); 7.53 (dd, 1H, H6 benzothiophenyl, J6,5 = 8.3 Hz, J6,7 = 7.1 Hz, J6,4 = 1.2 Hz); 7.60 (m, 
1H, H6’ quinoxalinyl); 7.71 (dd, 1H, H5’ quinoxalinyl, J5’,6’ = 8.4 Hz, J5’,7’ = 1.3 Hz); 7.91 (m, 2H, H8’ 
quinoxalinyl + H4 benzothiophenyl); 8.38 (s, 1H, H2 benzothiophenyl); 8.60 (s, 1H, H3’quinoxalinyl); 
8.79 (dd, 1H, H7 benzothiophenyl, J7,6 = 8.2 Hz, J7,5 = 0.7 Hz ) ppm; Anal. Calcd. for (C23H22N4OS) C, 
68.63; H, 5.51; N, 13.92. Found: C, 68.58; H, 5.42; N, 13.77.  
 
Dihydrochloride of 1-(5-fluorobenzo[b]thiophen-3-yl)-3-[4-(3-methoxyphenyl)piperazin-1-yl]propan-
1-ol (16). Yield 42%; Mp 135-137 ºC; 1H-NMR (DMSO-d6): δ 2.22-2.24 (m, 2H, CHOH-CH2); 3.12-
3.16 (m, 4H, 2H2 + 2H6 piperazine); 3.28-3.33 (m, 2H, CHCH2CH2); 3.56-3.58 (m, 2H, 1H3ec+1H5ec 
piperazine); 3.73 (s, 3H, OCH3); 3.79-3.82 (m, 2H, H3ax+H5ax piperazine); 4.52 (bs, 1H, OH); 5.03 (t, 
1H, CHOH, JCH-CH2 = 7.6 Hz); 6.44 (d, 1H, H4’ phenyl, J4’,5’ = 8.0 Hz, J4’,6’ = 2.0 Hz); 6.46 (s, 1H, H2’ 
phenyl); 6.52 (d, 1H, H6’ phenyl, J6’,5’ = 8.0 Hz, J6’,4’ = 2.0 Hz); 7.13 (t, 1H, H5’ phenyl, J5’,6’ = J5’,4’ = 
8.4 Hz); 7.27 (t, 1H, H6 benzothiophenyl, J6,7 = 8.8 Hz, J6,4 = 2.4 Hz); 7.77 (s, 1H, H2 
benzothiophenyl); 7.81 (d, 1H, H7 benzothiophenyl, J7,6 = 8.8 Hz); 8.03 (dd, 1H, H4 benzothiophenyl, 
J = 8.8 Hz)); 10.91 (s, 1H, OH); ppm; Anal. Calcd. for (C22H25FN2O2S. 2HCl) C, 55.81; H, 5.70; N, 
5.91. Found: C, 55.41; H, 5.82; N, 5.43.  
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1-(Benzo[b]thiophen-3-yl)-3-[4-(4-nitro-2-trifluoromethylphenyl)piperazin-1-yl]propan-1-ol (28). 
Yield 3%; Mp 154-155 ºC; 1H-NMR (CDCl3): 2.14-2.16 (m, 2H, CHOH-CH2); 2.77-2.87 (m, 6H, 
CHOH-CH2-CH2 + H2+H6 piperazine); 3.20-3.29 (m, 4H, H3+ H5 piperazine); 5.38 (t, 1H, CHOH, 
JCH-CH2 = 7.5 Hz); 7.33-7.42 (m, 3H, H6’ phenyl + H6 + H5 benzothiophenyl); 7.45 (s, 1H, H2 
benzothiophenyl); 7.82 (d, 1H, H4 benzothiophenyl, J4,5 = 8.4 Hz); 7.88 (d, 1H, H7 benzothiophenyl, 
J7,6 = 8.0 Hz); 8.37 (dd, 1H, H5’ phenyl J5’,6’ = 9.2 Hz, J5’,3’ = 2.8 Hz); 8.55 (d, 1H, H3’ phenyl) ppm; 
Anal. Calcd. for (C22H22N3F3O3S) C, 57.77; H, 4.73; N, 9.03. Found: C, 57.01; H, 4.85; N, 8.54.  
 
1-(Benzo[b]thiophen-3-yl)-3-[3-(4-nitro-2-trifluoromethylphenylamino)-(R)-pyrrolidin-1-yl]propan-1-
ol (29). Yield 47%; Mp 48-50 ºC; 1H-NMR (DMSO-d6): δ 1.82-1.89 (m, 1H, H4ec pyrrolidine); 2.06-
2.21 (m, 2H, CHOH-CH2); 2.47-2.56 (m, 1H, H4ax pyrrolidine); 2.76-2.85 (m, 3H, CHOH-CH2-CH2 + 
H2ec + H5ax pyrrolidine); 3.00-3.15 (m, 2H, CHOH-CH2-CH2 + H5ec pyrrolidine); 3.07-3.11 (m, 1H, 
H2ax pyrrolidine); 4.18-4.26 (m, 1H, H3 pyrrolidine); 5.27 (bs, 1H, NH); 5.36-5.38 (m, 1H, CHOH); 
6.72 (dd, 1H, H6’ phenyl, J6’,5’ = 9.3 Hz, J6’,3’ = 2.3 Hz); 7.34-7.40 (m, 2H, H5, H6 benzothiophenyl); 
7.44 (d, 1H, H2 benzothiophenyl, J = 7.3 Hz); 7.80-7.83 (m, 1H, H4 benzothiophenyl); 7.87-7.90 (m, 
1H, H7 benzothiophenyl); 8.29 (dd, 1H, H5’ phenyl, J5’,6’ = 9.4 Hz, J5’,3’ = 2.2 Hz); 8.44 (t, 1H, H3’ 
phenyl, J3’,F = J3’,5’ = 2.9 Hz) ppm; Anal. Calcd. for (C22H22N3F3O3S) C, 56.77; H, 4.76; N, 9.07. 
Found: C56.50; H, 4.88; N, 9.02.  
 
1-(Benzo[b]thiophen-3-yl)-3-[1-(4-nitro-2-trifluoromethylphenyl)-(S)-pyrrolidin-3-ylamino]propan-1-
ol (30). Yield 18%; Mp 109-110 ºC;. 1H-NMR (CDCl3): δ 1.94-2.07 (m, 2H, CHOH-CH2); 2.15-2.20 
(m, 1H, H4ec pyrrolidine); 2.24-2.31 (m, 1H, H4ax pyrrolidine); 2.91-3.00 (m, 1H, CHOH-CH2-CH2); 
3.04-3.10 (m, 1H, CHOH-CH2-CH2) 3.20 (bs, 1H, OH); 3.41 (td, 1H, H2ec pyrrolidine); 3.49-3.54 (m, 
1H, H5ec pyrrolidine); 3.58-3.65 (m, 1H, H2ax pyrrolidine); 3.72-3.80 (m, 2H, H5ax + H3 pyrrolidine); 
5.35 (bs, 1H, CHOH); 6.84 (dd, 1H, H6’, J6’,5’ = 9.5 Hz, H6’ phenyl, J6’,3’ = 2.5 Hz); 7.33-7.43 (m, 3H, 
H5 + H6 + H2 benzothiophenyl); 7.77-7.80 (m, 1H, H4 benzothiophenyl); 7.87-7.89 (m, 1H, H7 
benzothiophenyl); 8.18-8.22 (m, 1H, H5’ phenyl); 8.58 (dd, 1H, H3’ phenyl, J3’,5’ = 5.1 Hz, J3’,6’ = 2.6 
Hz) ppm; Anal. Calcd. for (C22H22N3F3O3S) C, 56.77; H, 4.76; N, 9.07. Found: C, 56.33; H, 4.94; N, 
9.06.  
 
1-(Benzo[b]thiophen-3-yl)-3-[1-(4-nitro-2-trifluoromethylphenyl)piperidin-4-ylamino]propan-1-ol  
(31). Yield 33%; Mp 145-146 ºC; 1H-NMR (CDCl3): δ 1.57-1.68 (m, 2H, H3ax + H5ax piperidine); 
1.94-2.03 (m, 1H, CHOH-CH2); 2.08 (d, 2H, H3ec + H5ec piperidine); 2.15-2.20 (m, 1H, CHOH-CH2); 
2.71-2.77 (m, 1H, H4 piperidine); 2.91-3.01 (m, 3H, H2ax + H6ax piperidine + CH2-NH); 3.07-3.12 (m, 
1H, CH2-NH); 3.41 (d, 2H, H2ec + H6ec piperidine); 5.38 (m, 1H, CHOH); 7.27 (d, 1H, H6’ phenyl, 
J6’,5’ = 8.9 Hz); 7.34-7.40 (m, 2H, H5 + H6 benzothiophenyl); 7.46 (s, 1H, H2 benzothiophenyl); 7.81 
(d, 1H, H4, benzothiophenyl J4,5 = 7.9 Hz); 7.88 (d, 1H, H7 benzothiophenyl, J7,6 = 7.8 Hz); 8.32 (dd, 
1H, H5’ phenyl, J5’,6’ = 9.0 Hz, J5’,3’ = 2.3 Hz); 8.53 (d, 1H, H3’ phenyl, J3’,5’ = 2.4 Hz) ppm; Anal. 
Calcd. for (C23H24N3F3O3S) C, 57.61; H, 5.04; N, 8.76. Found: C, 57.39; H, 5.06; N, 8.80.  
 
1-(5-Fluorobenzo[b]thiophen-3-yl)-3-[4-(4-nitrophenyl)piperazin-1-yl]propan-1-ol (32). Yield 14%; 
Mp 189-190 ºC; 1H-NMR (CDCl3): δ 1.60 (bs, 1H, OH); 2.10-2.15 (m, 2H, CHOH-CH2); 2.79-2.90 
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(m, 6H, CHOH-CH2-CH2 + H2+H6 piperazine); 3.53 (t, 4H, H3+ H5 piperazine); 5.30 (dd, 1H, 
CHOH); 6.88 (d, 2H, H2’+ H6’ phenyl, J2’,3’ = J6’,5’ = 9.4 Hz); 7.14 (td, 1H, H6 benzothiophenyl, J6,7 = 
J6,F = 8.7 Hz, J6,4 = 2.4 Hz); 7.50-7.53 (m, 2H, H2 + H4 benzothiophenyl); 7.81 (dd, 1H, H7 
benzothiophenyl, J7,6 = 8.8 Hz, J7,F = 4.8 Hz); 8.17 (d, 2H, H3’+ H5’ phenyl, J3’,4’ = J5’,6’ = 9.4 Hz) 
ppm; Anal. Calcd. for (C21H22N3FO3S) C, 60.71; H, 5.34; N, 10.11. Found: C, 60.44; H, 5.43; N, 9.79.  
1-(Benzo[b]thiophen-3-yl)-3-(1-(4-nitrophenyl)piperidin-4-ylamino)propan-1-ol (33). Yield 57%; Mp 
153-155 ºC; 1H-NMR (DMSO-d6): δ 1.23-1.31 (m, 2H, H3ax + H5ax piperidine); 1.86-1.96 (m, 4H, H3ec 
+ H5ec piperidine + CHOH-CH2); 2.69-2.73 (m, 3H, H2ax + H6ax + H4 piperidine); 3.07 (t, 2H, CH2-
NH); 3.95 (d, 2H, H2ec + H6ec piperidine); 5.08 (s.a., 1H, CHOH); 7.27 (d, 1H, H2’+ H6’ phenyl, J2’,3’ = 
J6’,5’ = 8.7 Hz); 7.33-7.39 (m, 2H, H5 + H6 benzothiophenyl); 7.53 (s, 1H, H2 benzothiophenyl); 7.93-
7.97 (m, 2H, H4 + H7 benzothiophenyl); 8.32 (dd, 1H, H3’+ H5’ phenyl, J3’,2’ = J5’,6’ = 8.8 Hz) ppm; 
Anal. Calcd. for (C22H25N3O3S) C, 64.21; H, 6.12; N, 10.21. Found: C, 64.00; H, 5.97; N, 10.43.  
 
1-(Benzo[b]thiophen-3-yl)-3-(4-(4-nitrophenyl)-1,4-diazepan-1-yl)propan-1-ol (34). Yield 61%; Mp 
47-48 ºC; 1H-NMR (DMSO-d6): δ 2.00-2.16 (m, 4H, 2H6 diazepane + CHOH-CH2); 2.68-3.00 (m, 6H, 
CH-CH2-CH2 + 2H2 + 2H7 diazepane); 3.64-3.68 (m, 2H, 2H5 diazepane); 3.74 (bs, 2H, 2H3 
diazepane); 5.32-5.38 (m, 1H, CHOH); 6.67 (d, 2H, H2’+ H6’ phenyl, J2’,3’ = J 6’,5’ = 9.4 Hz); 7.36-7.39 
(m, 2H, H6+H5 benzothiophenyl); 7.43 (s, 1H, H2 benzothiophenyl); 7.78 (d, 1H, H4, J4,5 = 7.42 
benzothiophenyl); 7.88 (d, 1H, H7 benzothiophenyl, J7,6 = 7.03 Hz); 8.15 (d, 2H, H3’+H5’ phenyl, J3’,2’ 
= J5’,6’ = 9.0 Hz) ppm; Anal. Calcd. for (C22H25N3O3S) C, 65.23; H, 6.08; N, 10.22. Found: C, 65.44; 
H, 6.45; N, 9.79. 
 
1-(Benzo[b]thiophen-3-yl)-3-(4-(quinoxalin-2-yl)piperazin-1-yl)propan-1-ol (35). Yield 15%; Mp 
155-156 ºC; 1H-NMR (DMSO-d6): δ 2.29-2.32 (m, 2H, CHOHCH2); 3.13-3.22 (m, 6H, CH-CH2-CH2 
+ 2H2 + 2H6 piperazine); 3.46-3.54 (m, 2H, H3 piperazine); 3.56-3.64 (m, 2H, H5 piperazine); 5.05-
5.07 (m, 1H, CHOH); 5.76 (bs, 1H, OH); 7.37-7.44 (m, 2H, H5 + H6 benzothiophenyl); 7.45-7.49 (m, 
1H, H7’ quinoxalinyl); 7.63-7.66 (m, 3H, H2 + H4 benzothiophenyl + H6’ quinoxalinyl); 8.88 (d, 1H, 
H7 benzothiophenyl, J7,6 =8.4); 7.99 (dd, 2H, H5’ + H8’ quinoxalinyl, J5’,6’ = J8’,7’ = 8.9 Hz, J5’,7’=J8’,6’ = 
1.2 Hz); 8.90 (s, 1H, H3’ quinoxalinyl) ppm; Anal. Calcd. for (C23H24N4OS) C, 68.31; H, 5.94; N, 
13.86. Found: C, 68.70; H, 6.22; N, 13.65.  
 
1-(4-Phenyl)phenyl -3-[4-(4-chlorophenyl)piperazin-1-yl]propan-1-ol (38). Yield 47%; Mp 169-170 
ºC; 1H-NMR (DMSO-d6): δ 1.80-1.85 (m, 2H, CHOHCH2); 3.12-3.16 (m, 6H, CH-CH2-CH2 + 2H2 + 
2H6 piperazine); 3.34 (bs, 4H, 2H3 + 2H5 piperazine); 4.68-4.70 (m, 1H, CHOH); 5.51 (s, 1H, OH); 
6.93 (d, 2H, H2+H6 Cl-phenyl, J = 9.0 Hz); 7.22 (d, 2H, H3+H5 Cl-phenyl, J = 8.8 Hz); 7.35 (t, 1H, H4’ 
phenyl, J = 8.4 Hz); 7.31-7.38 (m, 4H, H2+H6 p-phenylphenyl + H3’+H5’ phenyl); 7.61-7.67 (m, 4H, 
H3+H5 p-phenylphenyl + H2’+H6’ phenyl); ppm; Anal. Calcd. for (C25H27ClN2O) C, 73.80; H, 6.64; N, 
6.88. Found: C, 73.48; H, 6.89; N, 6.78.  
 
1-(4-Phenyl)phenyl-3-[4-(2-methoxyphenyl)piperazin-1-yl]propan-1-ol (40). Yield 77% yield; Mp 
109-110 ºC; 1H-NMR (DMSO-d6): δ 1.79-1.83 (m, 2H, CHOHCH2); 2.38-2.54 (m, 6H, CHCH2CH2 + 
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2H2 + 2H6 piperazine); 2.96 (bs, 4H, 2H3 + 2H5 piperazine); 3.76 (bs, 3H, OCH3); 4.70 (t, 1H, 
CHOH); 5.52 (bs, 1H, OH); 6.87-6.93 (m, 4H, H3+H4+H5+H6 OCH3-phenyl); 7.35 (t, 1H, H4’ 
phenyl); 7.42-7.48 (m, 4H, H2+H6 p-phenylphenyl + H3’+H5’ phenyl); 7.61-7.67 (m, 4H, H3+H5 p-
phenylphenyl + H2’+H6’ phenyl); ppm; Anal. Calcd. for (C26H30N2O2) C, 77.61; H, 7.46; N, 6.96. 
Found: C, 77.58; H, 7.75; N, 6.84.  
 
1-(3-Indolyl)-3-[4-(2-methoxyphenyl)piperazin-1-yl]propan-1-ol (41). Yield 30% yield; Mp 188-189 
ºC; 1H-NMR (DMSO-d6): δ 1.91-2.03 (m, 2H, CHOHCH2); 2.38-2.51 (m, 6H, CHCH2CH2 + 2H2 + 
2H6 piperazine); 2.96 (bs, 4H, 2H3 + 2H5 piperazine); 3.76 (s, 3H, OCH3); 4.92 (t, 1H, CHOH); 5.16 
(bs, 1H, OH); 6.87-6.98 (m, 5H, H3’+H4’+H5’+H6’ phenyl + H6 indolyl); 7.04-7.06 (t, 1H, H5 indolyl, 
J5,6 = 8.0 Hz, J5,4 = 7.4 Hz); 7.20 (s, 1H, H2 indolyl); 7.33 (d, 1H, H7 indolyl, J7,6 = 8.4 Hz); 7.63 (d, 
1H, H4 indolyl, J4,5 = 7.4 Hz); 10.83 (s, 1H, NH) ppm; Anal. Calcd. for (C22H27N3O2) C, 72.33; H, 
7.39; N, 11.51. Found: C, 72.23; H, 7.85; N, 11.19.  
 
Dihydrochloride of 1-(6-methylnapth-2-yl)-3-[4-(2-methoxyphenyl) piperazin-1-yl]propan-1-ol (44). 
Yield 35%; M.p.: 116-117 ºC; 1H-NMR (DMSO-d6): δ 2.10-2.19 (m, 2H, CHCH2); 2.47 (s, 3H, CH3); 
2.95-3.02 (m, 2H, H2ax + H6ax piperazine); 3.16-3.29 (m, 4H, H2ec + H6ec piperazine + CHCH2CH2); 
3.45-3.57 (m, 4H, H3 + H5 piperazine); 3.78 (s, 3H, OCH3); 4.80-4.83 (m, 1H, CH); 6.91-7.05 (m, 4H, 
H3’+H4’+H5’+H6’ phenyl); 7.36 (d, 1H, H7 naphthyl, J7,8 = 8.4 Hz); 7.50 (d, 1H, H3 naphthyl, J3,4 = 8.8 
Hz); 7.67 (s, 1H, H5 naphthyl); 7.81 (m, 3H, H1+H4+H8 naphthyl) ppm; Anal. Calcd. for (C25H30N2O2. 
2HCl) C, 64.79; H, 6.91; N, 6.04. Found: C, 64.62; H, 7.05; N, 5.88.  
 
Hydrochloride of 1-(2-naphthyl)-3-[3-(4-nitro-2-trifluoromethylphenyl)-(S)-pyrrolidin-3-yl amino]-
propan-1-ol (45). Yield 20%; Mp.: 181-183 ºC; 1H-NMR (DMSO-d6): δ 2.07-2.14 (m, 2H, CHOH-
CH2); 2.29-2.31 (m, 1H, H4ec pyrrolidine); 2.36-2.41 (m, 1H, H4ax pyrrolidine); 3.11 (bs, 2H, CHOH-
CH2-CH2); 3.57-3.64 (m, 1H, H2ec pyrrolidine); 3.75-3.79 (m, 2H, H5ec+ H2ax pyrrolidine); 3.85-3.89 
(m, 1H, H5ax pyrrolidine); 3.97 (bs, 1H, H3 pyrrolidine); 5.90 (bs, 1H, CHOH); 5.76 (s, 1H, OH); 7.10 
(d, 1H, H6’ phenyl, J6’,5’ = 9.6); 7.47-7.55 (m, 3H, H3 + H6 + H7 naphthyl); 7.86 (s, 1H, H1 naphthyl); 
7.90-7.92 (m, 3H, H4 + H5 + H8 naphthyl); 8.24-8.9 (d, 1H, H5’ phenyl, J5’,6’ = 9.5); 8.40 (s, 1H, H3’ 
phenyl); 9.49 (bs, 1H, NH) ppm; Anal. Calcd. for (C24H24N3F3O3.HCl) C, 58.24; H, 5.04; N, 8.48. 
Found: C, 57.87; H, 4.92; N, 8.21.  
4. Conclusions  
The biological evaluation showed a broad range of activities, thereby offering new structural hits 
for future chemical pharmacomodulation of 1-aryl-3-substituted propanol derivatives as a new 
therapeutic option for the treatment of malaria. 
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